The JAK Inhibitor Experience in Rheumatology
Dr. Roy Fleischmann discusses JAK inhibitors from a rheumatologist’s perspective, addressing their structure and function as well as the pathways utilizing JAKs, and the safety and utility of these drugs across a variety of disease states. This is Part 1 in a 3-part series. Roy Fleischmann, MD, MACR, is Clinical Professor of Medicine at the […]